Adverse Adolescent Pathways to Substance Use
Eligible age
12–14 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Purpose: This 5-year R01 study will elucidate the role of maturational change across adolescence in neural connectivity and physiological stress responses in the relationship between anxiety and adverse pathways to substance use (APSU). Participants: Children (N=200) aged 12-14 with symptoms of anxiety and their legal caregiver will be recruited from clinical and community sources. Procedures: Youth participants will complete several questionnaires and interviews, undergo neuroimaging while performing cognitive tasks, and have their heart rate and skin conductance monitored during a mildly stressful task. Caregivers will complete several questionnaires.
Sponsor: University of North Carolina, Chapel Hill
You may qualify if…
- ✓ Male or female
- ✓ 12-14 years old,
- ✓ Report symptoms of anxiety
- ✓ Understand and sign an assent, and parents will sign a permission and a consent document in English
- ✓ Meets study hearing and vision requirements
- ✓ Substance use naïve
You may not qualify if…
- ✕ Has any foreign metal objects or implants as determined by the safety questionnaires (e.g., bone screws, shunts or body piercing that can't be removed, etc.)
- ✕ Has been diagnosed with psychosis or a severe emotional disturbance.
- ✕ Has used alcohol, tobacco, or marijuana more than 3 times.
- ✕ Is pregnant. Girls who self-report pregnancy may not participate in the stress evaluation or the MRI scan.
- ✕ Is taking any medications that directly alter cardiovascular function (e.g., propranolol or other beta blockers).
- ✕ Any current or lifetime treatment with antipsychotic medication.
- ✕ Has had a head injury that resulted in a loss of consciousness for more than 5 minutes.
- ✕ Is planning to get non-removable metal braces.
Where it's recruiting
Chapel Hill
Source: ClinicalTrials.gov · NCT06977178 · last updated 2025-05-18